>Marché européen du traitement de l'anthrax, par type ( anthrax cutané , anthrax pulmonaire et anthrax intestinal), voie d'administration (orale, parentérale et autres), utilisateur final (organisme gouvernemental, hôpitaux, instituts universitaires et de recherche, et autres) Tendances et prévisions de l'industrie jusqu'en 2029.
Analyse et perspectives du marché du traitement de l'anthrax en Europe
Le marché européen du traitement de l'anthrax est stimulé par des facteurs tels que l'incidence croissante des infections bactériennes , l'augmentation du financement de la recherche et le développement de nouvelles thérapies pour le traitement de l'anthrax et les produits en cours de développement qui augmentent sa demande, ainsi que l'augmentation des investissements dans la recherche et le développement qui conduisent à la croissance du marché. Actuellement, les dépenses de santé ont augmenté dans les pays développés et émergents, ce qui devrait créer un avantage concurrentiel pour les fabricants qui souhaitent développer des produits nouveaux et innovants.
L'augmentation du nombre de personnes souffrant de l'anthrax dans le monde est l'un des principaux facteurs de croissance du marché du traitement de l'anthrax. L'augmentation du soutien financier aux chercheurs pour le développement de nouvelles interventions et l'augmentation de la menace d'exposition au Bacillus anthracis parmi les populations civiles et les forces militaires accélèrent la croissance du marché. L'augmentation du nombre de programmes de recherche et développement et l'augmentation des partenariats public-privé pour faciliter les développements de nouveaux traitements innovants et efficaces influencent davantage le marché. Cependant, le coût élevé associé au traitement et à la procédure ainsi que les réglementations gouvernementales strictes pour l'approbation des produits devraient entraver la croissance du marché du traitement de l'anthrax.
Le rapport sur le marché du traitement de l'anthrax en Europe fournit des détails sur la part de marché, les nouveaux développements et l'analyse du pipeline de produits, l'impact des acteurs du marché national et localisé, analyse les opportunités en termes de poches de revenus émergentes, les changements dans la réglementation du marché , les approbations de produits, les décisions stratégiques, les lancements de produits, les expansions géographiques et les innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché, contactez-nous pour un briefing d'analyste, notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité. L'évolutivité et l'expansion commerciale des unités de vente au détail dans les pays en développement de diverses régions et le partenariat avec les fournisseurs pour une distribution sûre de machines et de produits pharmaceutiques sont les principaux moteurs qui ont propulsé la demande du marché au cours de la période de prévision.
Le marché européen du traitement de l'anthrax est favorable et vise à réduire la progression de la maladie. Data Bridge Market Research analyse que le marché européen du traitement de l'anthrax connaîtra un TCAC de 5,7 % au cours de la période de prévision de 2022 à 2029.
|
Rapport métrique |
Détails |
|
Période de prévision |
2022 à 2029 |
|
Année de base |
2021 |
|
Années historiques |
2020 (personnalisable de 2019 à 2014) |
|
Unités quantitatives |
Revenue in USD Million, Pricing in USD |
|
Segments Covered |
By Type (Cutaneous Anthrax, Pulmonary Anthrax and Intestinal Anthrax), Route of Administration (Oral, Parenteral and Others),End User (Government Organization, Hospitals, Academic and Research Institutes, and Others) Industry Trends and Forecast to 2029 |
|
Countries Covered |
Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Rest of Europe |
|
Market Players Covered |
Alembic Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Zydus Group, Bayer AG, Pfizer Inc., EMERGENT, Sanofi, Porton Biopharma, Lupin, Soligenix, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., ARISTO Pharmaceuticals Private Limited, INDOCO REMEDIES LTD., DEINOVE, among others |
Europe Anthrax Treatment Market Dynamics
Market Definition
Anthrax is caused by a bacterium called Bacillus anthracis (B. anthracis). It is primarily a disease of livestock that become infected by ingesting spores found in soil. Humans usually become infected with anthrax by handling products of infected animals such as leather or wool or by inhaling anthrax spores from infected animal products. They can also become infected by eating undercooked meat from infected animals. Anthrax is not known to be spread person-to-person.
Three clinical forms of anthrax infection exist. Cutaneous anthrax is the most common, constituting over 95% of reported cases. An estimated 2000 cases of cutaneous anthrax occur worldwide annually and result from the entry of spores through skin abrasions.
The differential diagnosis of anthrax includes depending on the clinical features, relevant specimens include PCR, gram stain, and cultures, from blood, pleural fluid, site of ulceration, cerebrospinal, and stool. A number of available techniques are available. Most assays are based on detecting the entire organism, organism antigens, or organism nucleic acid through one of the following techniques: culture-based conventional methods; immunological detection; nucleic-acid-based assays; ligand-based detection; and biosensors.
Drivers
- Increasing Prevalence of Anthrax Infections
The incidence of bacterial infections is increasing worldwide. Anthrax is a bacterial infection caused by Bacillus anthracis which is an aerobic, gram-positive spore-forming bacterium. Depending on the route of entry of B. anthracis spores, it occurs primarily as a cutaneous, pulmonary, or gastrointestinal infection. A characteristic black, crusty spot develops on the affected skin area later and, after a few weeks, begins to loosen and ultimately falls off, leaving a scar. The course of these events is so characteristic that the diagnosis is not often missed by physicians familiar with the disease, even though it is rare. Pulmonary anthrax is the most lethal of the three types of anthrax in which, the spores once inhaled germinate within the tracheobronchial lymph nodes and multiply. Anthrax is a harmful disease that affects both humans and animals. It is a life-threatening infection caused by Bacillus anthracis. Thus, this increasing incidence and prevalence of anthrax infections has developed a need of more diagnostic approaches with increased sensitivity that can detect infection in low volume.
The increase in the number of people suffering from anthrax across the globe acts as one of the major factors driving the growth of anthrax treatment market. The increase in the financial support to the researchers for developing novel intervention, and rise in threat of exposure to Bacillus anthracis among civilian populations and military forces accelerate the market growth. The increase in the number of research and development programs, and rise in public-private partnerships for facilitating novel developments for the innovative and effective treatment further influence the market.
- Increasing Research Funding and the development of novel therapies for anthrax treatment population
Research and development is a prerequisite in order to modify the procedure intended to treat different kinds of patients. The demand of anthrax treatment is increasing worldwide involving every country. This is why the companies are continuously focusing towards research and development in order to achieve success in providing effective treatment to patients. In these recent years many diagnostic approaches have come forward to take diagnosis to new steps, and many are being made to detect even the lowest volume of parasite in human body.
These new approaches in diagnosis will take the market forward. With the increase in research funding and the development of novel therapies for the treatment of anthrax. There are several novel and pre-existing antibiotics, as well as toxin inhibitors that have shown increasing promise that targets both bacterial growth as well as toxin production for effectively work against anthrax bacterium.
As the companies are constantly engaged in developmental activities more innovative products are launched in the market. The new tools developed have the efficiency to detect bacterial infection in fewer intervals of time with higher efficacy rate, which allows consumers to achieve appropriate treatment at correct time. Thus, this signifies that increasing research and development is expected as driver for the Europe anthrax treatment market growth
Opportunities
- Rising product launch
Human infection is usually via contact with infected animals or animal products and may manifest as a cutaneous, inhalational, or gastrointestinal infection. The worldwide incidence of anthrax is generally increasing. Therefore, the growing patient pool of the disease across the world is demanding highly effective and advanced anthrax treatment products to minimize the risk of death owing to anthrax disease. Moreover, the healthcare systems from developed countries prefer the high advancement with fewer risk factors and advanced anthrax treatment products. Owing to this, major market players are highly focused on product launches.
Thus growing product launches provide highly effective and advanced medical treatment products for a better patient experience. New product launches generate attention for the company as well as create the company's presence in the Europe market. The fundamental beneficial factor of the product launch is escalating the company’s business growth. Whereas new product launches create the revenue stream for the company and the revenue stream that establish with the product launch can be persistent for many years. Owing to this, it is estimated that new product launches is expected a tremendous opportunity for the market players to elevate their business growth in the anthrax treatment market.
Restraints/Challenges
- High cost of treatment
The cost of the product plays a major factor in the market. Many diagnostic options are available in the market, but due to their high cost, most people tend to avoid going for a diagnosis. Since diagnostic approaches have come with greater sensitivity and specificity cost of the test also increased. The high cost of the procedure is due to the various checkpoints of the treatments along with the use of high-tech modalities to perform such procedures. As the cost of technological advanced devices is high, the procedure cost proportionally gets escalated, due to which high cost of the procedure is expected to hamper the demand of the market.
De plus, les infections asymptomatiques doivent passer par des tests très spécifiques pour l'identification des bactéries qui sont coûteux. Étant donné le coût élevé du diagnostic de l'anthrax, on s'attend à ce qu'il freine la croissance du marché. Le coût des traitements d'identification étant trop élevé, il empêche les médecins et les patients de s'adapter à une solution de haute qualité et efficace. Désormais, le coût élevé des procédures de traitement a un impact négatif sur le coût du traitement global. Par conséquent, il limitera la demande future de traitement dans les pays à revenu faible et intermédiaire. Cela suggère que les procédures coûteuses devraient agir comme un frein à la croissance du marché européen du traitement de l'anthrax.
Développement récent
- En juin 2022, Emergent BioSolutions Inc. a annoncé que la Food and Drug Administration (FDA) des États-Unis a accepté d'examiner la demande de licence de produit biologique (BLA) pour AV7909, un nouveau candidat vaccin contre l'anthrax évalué pour la prophylaxie post-exposition de la maladie après une exposition suspectée ou confirmée à Bacillus anthracis chez les personnes âgées de 18 à 65 ans avec des médicaments antibactériens recommandés.
- En janvier 2022, Alembic Pharmaceuticals Limited a annoncé que la société avait reçu l'approbation finale de la Food & Drug Administration (USFDA) des États-Unis pour sa demande abrégée de nouveau médicament (ANDA) pour les comprimés à libération retardée d'hyclate de doxycycline USP, 75 mg, 100 mg, 150 mg et 200 mg, qui sont utilisés uniquement pour traiter ou prévenir les infections dont il est prouvé ou fortement suspecté qu'elles sont causées par des bactéries sensibles. Cela se traduit par une expansion du portefeuille de produits de la société.
Segmentation du marché du traitement de l'anthrax en Europe
Le marché européen du traitement de l'anthrax est classé en trois segments notables en fonction du type, de la voie d'administration et de l'utilisateur final. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et la différence entre vos marchés cibles.
Taper
- Charbon cutané
- Charbon pulmonaire
- Charbon intestinal
Sur la base du type, le marché européen du traitement de l’anthrax est segmenté en anthrax cutané, anthrax pulmonaire et anthrax intestinal.
Voie d'administration
- Charbon cutané
- Charbon pulmonaire
- Charbon intestinal
Sur la base de la voie d’administration, le marché européen du traitement de l’anthrax est segmenté en voie orale, parentérale et autres.
Utilisateur final
- Organisation gouvernementale
- Hôpitaux
- Instituts universitaires et de recherche,
- Autres
Sur la base de l'utilisateur final, le marché européen du traitement de l'anthrax est segmenté en organisations gouvernementales, hôpitaux, instituts universitaires et de recherche, et autres.
Analyse/perspectives régionales du marché du traitement de l'anthrax
Le marché européen du traitement de l’anthrax est analysé et des informations sur la taille du marché et les tendances sont fournies par type, voie d’administration et utilisateur final, comme référencé ci-dessus.
Les pays couverts par le rapport sur le traitement de l’anthrax sont l’Allemagne, la France, l’Italie, le Royaume-Uni, l’Espagne, les Pays-Bas, la Russie, la Suisse, la Turquie, la Belgique et le reste de l’Europe.
L’Allemagne devrait dominer le marché en raison des progrès technologiques croissants dans les régions en développement.
La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces du porteur, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques européennes et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et des routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché du traitement de l'anthrax
Le paysage concurrentiel du marché européen du traitement de l'anthrax fournit des détails par concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence en Europe, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises sur le marché du traitement de l'anthrax.
Certains acteurs du marché sont Alembic Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Zydus Group, Bayer AG, Pfizer Inc., EMERGENT, Sanofi, Porton Biopharma, Lupin, Soligenix, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., ARISTO Pharmaceuticals Private Limited, INDOCO REMEDIES LTD., DEINOVE, entre autres.
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. Les données du marché sont analysées et estimées à l'aide de modèles statistiques et cohérents du marché. En outre, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. La principale méthodologie de recherche utilisée par l'équipe de recherche DBMR est la triangulation des données, qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). En dehors de cela, les modèles de données comprennent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement de l'entreprise, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse des parts de marché Europe vs région et des fournisseurs. Veuillez demander un appel d'analyste en cas de demande de renseignements supplémentaires.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE ANTHRAX TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 DEMOGRAPHIC TRENDS-
4.4 EPIDEMIOLOGY AND DEMOGRAPHICS-
4.4.1 INCIDENCE
4.4.2 DEVELOPED COUNTRIES-
4.4.3 DEVELOPING COUNTRIES-
4.5 PATIENT ENROLMENT STRATEGIES-
4.6 PATIENT FLOW DIAGRAM FOR ANTHRAX INFECTION-
4.7 CURRENT STATE OF ANTHRAX VACCINES
4.8 EUROPE ANTIBIOTIC CONSUMPTION RATES INCREASED BY 46 PERCENT IN THE LAST TWO DECADES, ACCORDING TO THE FIRST STUDY TO PROVIDE LONGITUDINAL ESTIMATES FOR HUMAN ANTIBIOTIC CONSUMPTION COVERING 204 COUNTRIES FROM 2000 TO 2018.
4.9 EUROPE ANTIBIOTIC CONSUMPTION AND PROJECTED CONSUMPTION-
5 THE M&A IN THE ANTHRAX MARKET INDICATES AN UPCOMING LONG RUN IN VACCINE DEVELOPMENT AROUND THE GLOBE. CURRENT AND SOME OF LAST YEAR’S ACQUISITION BETWEEN LEADERS AND SMALL SIZE PHARMACEUTICAL SHOWS THE CONTINUOUS DEVELOPMENT IN THE COMPANY’S PIPELINE FOR ANTHRAX TREATMENT.
6 EUROPE ANTHRAX TREATMENT MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING INCIDENCE OF ANTHRAX INFECTION
7.1.2 INCREASE IN RESEARCH FUNDING AND THE DEVELOPMENT OF NOVEL THERAPIES FOR THE TREATMENT OF ANTHRAX
7.1.3 TECHNOLOGICAL ADVANCEMENTS IN TREATMENT PROCEDURE
7.1.4 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS
7.2 RESTRAINTS
7.2.1 HIGH COST ASSOCIATED WITH ANTHRAX DIAGNOSTIC TREATMENT
7.2.2 FALSE DATA INTERPRETATION
7.3 OPPORTUNITIES
7.3.1 RISING PRODUCT LAUNCHES
7.3.2 RISING GOVERNMENT INITIATIVES
7.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM
7.4 CHALLENGES
7.4.1 LACK OF AWARENESS AMONG PEOPLE ABOUT ANTHRAX INFECTION
7.4.2 LACK OF SKILLED PROFESSIONALS
8 EUROPE ANTHRAX TREATMENT MARKET, BY TYPE
8.1 OVERVIEW
8.2 CUTANEOUS ANTHRAX
8.2.1 ANTIBIOTICS
8.2.1.1 BY DRUGS
8.2.1.1.1 CIPROFLOXACIN
8.2.1.1.2 LEVOFLOXACIN
8.2.1.1.3 DOXYCYCLINE
8.2.1.1.4 AMPICILLIN
8.2.1.1.5 OTHERS
8.2.1.2 BY PRODUCT TYPES
8.2.1.2.1 GENERICS
8.2.1.2.2 BRANDED
8.2.1.2.2.1 CIPRO
8.2.1.2.2.2 LEVO
8.2.1.2.2.3 DOXY
8.2.1.2.2.4 AMPICI
8.2.1.2.2.5 OTHERS
8.2.2 ANTITOXINS
8.2.2.1 RAXIBACUMAB
8.2.2.2 OBILTOXAXIMAB (ANTHIM)
8.2.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS)
8.2.2.4 OTHERS
8.2.3 VACCINES
8.2.3.1 RAXIBACUMAB
8.2.4 SURGERY
8.3 PULMONARY ANTHRAX
8.3.1 ANTIBIOTICS
8.3.1.1 BY DRUGS
8.3.1.1.1 CIPROFLOXACIN
8.3.1.1.2 LEVOFLOXACIN
8.3.1.1.3 DOXYCYCLINE
8.3.1.1.4 AMPICILLIN
8.3.1.1.5 OTHERS
8.3.1.2 BY PRODUCT TYPES
8.3.1.2.1 GENERICS
8.3.1.2.2 BRANDED
8.3.1.2.2.1 CIPRO
8.3.1.2.2.2 LEVO
8.3.1.2.2.3 DOXY
8.3.1.2.2.4 AMPICI
8.3.1.2.2.5 OTHERS
8.3.2 ANTITOXINS
8.3.2.1 RAXIBACUMAB
8.3.2.2 OBILTOXAXIMAB (ANTHIM)
8.3.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS)
8.3.2.4 OTHERS
8.3.3 VACCINES
8.3.3.1 RAXIBACUMAB
8.3.3.2 SURGERY
8.4 INTESTINAL ANTHRAX
8.4.1 ANTIBIOTICS
8.4.1.1 BY DRUGS
8.4.1.1.1 CIPROFLOXACIN
8.4.1.1.2 LEVOFLOXACIN
8.4.1.1.3 DOXYCYCLINE
8.4.1.1.4 AMPICILLIN
8.4.1.1.5 OTHERS
8.4.1.2 BY PRODUCT TYPES
8.4.1.2.1 GENERICS
8.4.1.2.2 BRANDED
8.4.1.2.2.1 CIPRO
8.4.1.2.2.2 LEVO
8.4.1.2.2.3 DOXY
8.4.1.2.2.4 AMPICI
8.4.1.2.2.5 OTHERS
8.4.2 ANTITOXINS
8.4.2.1 RAXIBACUMAB
8.4.2.2 OBILTOXAXIMAB (ANTHIM)
8.4.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS)
8.4.2.4 OTHERS
8.4.3 VACCINES
8.4.3.1 RAXIBACUMAB
8.4.3.2 SURGERY
9 EUROPE ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 PARENTERAL
9.3 ORAL
9.4 OTHERS
10 EUROPE ANTHRAX TREATMENT MARKET, BY END USER
10.1 OVERVIEW
10.2 GOVERNMENT ORGANIZATION
10.3 HOSPITALS
10.4 ACADEMIC AND RESEARCH
10.5 OTHERS
11 EUROPE VIRTUAL REALITY MARKET, BY GEOGRAPHY
11.1 EUROPE
11.1.1 GERMANY
11.1.2 FRANCE
11.1.3 U.K.
11.1.4 ITALY
11.1.5 RUSSIA
11.1.6 SPAIN
11.1.7 TURKEY
11.1.8 NETHERLANDS
11.1.9 SWITZERLAND
11.1.10 BELGIUM
11.1.11 REST OF EUROPE
12 EUROPE ANTHRAX TREATMENT MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: EUROPE
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 BAYER AG
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENTS
14.2 PFIZER INC.
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 TEVA PHARMACEUTICAL INDUSTRIES LTD
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 SANOFI
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED.
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENT
14.6 ALEMBIC PHARMACEUTICALS LIMITED
14.6.1 COMPANY SNAPSHOT
14.6.2 PRODUCT PORTFOLIO
14.6.3 RECENT DEVELOPMENTS
14.7 ALTIMMUNE
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENTS
14.8 ARISTO PHARMACEUTICALS PRIVATE LIMITED
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENTS
14.9 BLUEWILLOW BIOLOGICS.
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENTS
14.1 DEINOVE
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENTS
14.11 EMERGENT
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENTS
14.12 ELUSYS THERAPEUTICS INC.
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 GC BIOPHARMA CORP.
14.13.1 COMPANY SNAPSHOT
14.13.2 REVENUE ANALYSIS
14.13.3 PRODUCT PORTFOLIO
14.13.4 RECENT DEVELOPMENTS
14.14 INDOCO REMEDIES LTD.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENTS
14.15 INTEGRATED BIOTHERAPEUTICS, INC.
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENTS
14.16 LUPIN.
14.16.1 COMPANY SNAPSHOT
14.16.2 REVENUE ANALYSIS
14.16.3 PRODUCT PORTFOLIO
14.16.4 RECENT DEVELOPMENTS
14.17 PARATEK PHARMACEUTICALS, INC.
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENTS
14.18 PORTON BIOPHARMA
14.18.1 COMPANY SNAPSHOT
14.18.2 PRODUCT PORTFOLIO
14.18.3 RECENT DEVELOPMENTS
14.19 SOLIGENIX
14.19.1 COMPANY SNAPSHOT
14.19.2 REVENUE ANALYSIS
14.19.3 PRODUCT PORTFOLIO
14.19.4 RECENT DEVELOPMENTS
14.2 SUN PHARMACEUTICAL INDUSTRIES LTD.
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENTS
14.21 ZYDUS GROUP
14.21.1 COMPANY SNAPSHOT
14.21.2 REVENUE ANALYSIS
14.21.3 PRODUCT PORTFOLIO
14.21.4 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
Liste des tableaux
TABLE 1 POPULATION AT RISK (IN MILLIONS) BY REGION, LAND USE AND OCCUPATIONAL EXPOSURE, 2020-
TABLE 2 VACCINES IN DEVELOPMENT
TABLE 3 ANTIBIOTIC CONSUMPTION ESTIMATES BY GBD SUPER-REGION AND GBD REGION, FOR THE YEAR 2018-
TABLE 4 COUNTRY DATA OF ANTIBIOTICS CONSUMPTION-
TABLE 5 RECENT M&A IN ANTHRAX MARKET-
TABLE 6 ANTIBIOTICS MEDICINES
TABLE 7 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED
TABLE 8 EUROPE ANTHRAX TREATMENT MARKET, TYPE, 2020-2029 (USD MILLION)
TABLE 9 EUROPE CUTANEOUS ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 11 EUROPE ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 12 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 EUROPE BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 EUROPE BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 EUROPE ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 EUROPE VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 EUROPE PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 EUROPE PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 EUROPE ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 20 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 21 EUROPE BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 22 EUROPE BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 23 EUROPE ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 24 EUROPE VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 25 EUROPE INTESTINAL ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE INTESTINAL ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 27 EUROPE ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 28 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 29 EUROPE BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 30 EUROPE BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 31 EUROPE ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 32 EUROPE VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 33 EUROPE ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 34 EUROPE PARENTERAL IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 EUROPE ORAL IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 EUROPE OTHERS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 EUROPE ANTHRAX TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 38 EUROPE GOVERNMENT ORGANIZATION IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 EUROPE HOSPITALS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 EUROPE ACADEMIC AND RESEARCH IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 EUROPE OTHERS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 42 EUROPE ANTHRAX TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 43 EUROPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 EUROPE CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 45 EUROPE ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 46 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 47 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 48 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 49 EUROPE BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 50 EUROPE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 51 EUROPE BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 52 EUROPE BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 53 EUROPE ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 54 EUROPE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 55 EUROPE BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 56 EUROPE VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 57 EUROPE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 58 EUROPE BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 59 EUROPE PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 60 EUROPE ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 61 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 62 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 63 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 64 EUROPE BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 65 EUROPE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 66 EUROPE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 67 EUROPE BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 68 EUROPE ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 69 EUROPE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 70 EUROPE BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 71 EUROPE VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 72 EUROPE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 73 EUROPE BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 74 EUROPE INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 75 EUROPE ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 76 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 77 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 78 EUROPE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 79 EUROPE BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 80 EUROPE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 81 EUROPE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 82 EUROPE BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 83 EUROPE ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 84 EUROPE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 85 EUROPE BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 86 EUROPE VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 87 EUROPE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 88 EUROPE BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 89 EUROPE ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 90 EUROPE ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 91 GERMANY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 GERMANY CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 93 GERMANY ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 94 GERMANY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 95 GERMANY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 96 GERMANY BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 97 GERMANY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 98 GERMANY BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 99 GERMANY ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 100 GERMANY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 101 GERMANY VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 102 GERMANY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 103 GERMANY PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 104 GERMANY ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 105 GERMANY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 106 GERMANY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 107 GERMANY BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 108 GERMANY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 109 GERMANY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 110 GERMANY ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 111 GERMANY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 112 GERMANY VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 113 GERMANY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 114 GERMANY INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 115 GERMANY ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 116 GERMANY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 117 GERMANY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 118 GERMANY BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 119 GERMANY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 120 GERMANY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 121 GERMANY ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 122 GERMANY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 123 GERMANY VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 124 GERMANY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 125 GERMANY ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 126 GERMANY ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 127 FRANCE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 FRANCE CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 129 FRANCE ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 130 FRANCE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 131 FRANCE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 132 FRANCE BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 133 FRANCE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 134 FRANCE BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 135 FRANCE ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 136 FRANCE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 137 FRANCE VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 138 FRANCE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 139 FRANCE PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 140 FRANCE ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 141 FRANCE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 142 FRANCE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 143 FRANCE BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 144 FRANCE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 145 FRANCE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 146 FRANCE ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 147 FRANCE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 148 FRANCE VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 149 FRANCE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 150 FRANCE INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 151 FRANCE ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 152 FRANCE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 153 FRANCE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 154 FRANCE BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 155 FRANCE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 156 FRANCE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 157 FRANCE ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 158 FRANCE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 159 FRANCE VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 160 FRANCE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 161 FRANCE ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 162 FRANCE ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 163 U.K. ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 164 U.K. CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 165 U.K. ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 166 U.K. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 167 U.K. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 168 U.K. BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 169 U.K. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 170 U.K. BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 171 U.K. ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 172 U.K. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 173 U.K. VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 174 U.K. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 175 U.K. PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 176 U.K. ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 177 U.K. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 178 U.K. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 179 U.K. BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 180 U.K. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 181 U.K. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 182 U.K. ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 183 U.K. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 184 U.K. VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 185 U.K. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 186 U.K. INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 187 U.K. ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 188 U.K. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 189 U.K. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 190 U.K. BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 191 U.K. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 192 U.K. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 193 U.K. ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 194 U.K. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 195 U.K. VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 196 U.K. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 197 U.K. ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 198 U.K. ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 199 ITALY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 200 ITALY CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 201 ITALY ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 202 ITALY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 203 ITALY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 204 ITALY BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 205 ITALY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 206 ITALY BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 207 ITALY ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 208 ITALY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 209 ITALY VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 210 ITALY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 211 ITALY PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 212 ITALY ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 213 ITALY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 214 ITALY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 215 ITALY BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 216 ITALY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 217 ITALY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 218 ITALY ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 219 ITALY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 220 ITALY VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 221 ITALY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 222 ITALY INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 223 ITALY ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 224 ITALY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 225 ITALY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 226 ITALY BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 227 ITALY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 228 ITALY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 229 ITALY ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 230 ITALY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 231 ITALY VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 232 ITALY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 233 ITALY ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 234 ITALY ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 235 RUSSIA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 236 RUSSIA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 237 RUSSIA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 238 RUSSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 239 RUSSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 240 RUSSIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 241 RUSSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 242 RUSSIA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 243 RUSSIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 244 RUSSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 245 RUSSIA VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 246 RUSSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 247 RUSSIA PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 248 RUSSIA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 249 RUSSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 250 RUSSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 251 RUSSIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 252 RUSSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 253 RUSSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 254 RUSSIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 255 RUSSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 256 RUSSIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 257 RUSSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 258 RUSSIA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 259 RUSSIA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 260 RUSSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 261 RUSSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 262 RUSSIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 263 RUSSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 264 RUSSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 265 RUSSIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 266 RUSSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 267 RUSSIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 268 RUSSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 269 RUSSIA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 270 RUSSIA ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 271 SPAIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 272 SPAIN CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 273 SPAIN ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 274 SPAIN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 275 SPAIN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 276 SPAIN BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 277 SPAIN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 278 SPAIN BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 279 SPAIN ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 280 SPAIN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 281 SPAIN VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 282 SPAIN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 283 SPAIN PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 284 SPAIN ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 285 SPAIN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 286 SPAIN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 287 SPAIN BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 288 SPAIN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 289 SPAIN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 290 SPAIN ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 291 SPAIN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 292 SPAIN VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 293 SPAIN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 294 SPAIN INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 295 SPAIN ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 296 SPAIN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 297 SPAIN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 298 SPAIN BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 299 SPAIN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 300 SPAIN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 301 SPAIN ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 302 SPAIN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 303 SPAIN VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 304 SPAIN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 305 SPAIN ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 306 SPAIN ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 307 TURKEY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 308 TURKEY CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 309 TURKEY ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 310 TURKEY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 311 TURKEY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 312 TURKEY BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 313 TURKEY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 314 TURKEY BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 315 TURKEY ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 316 TURKEY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 317 TURKEY VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 318 TURKEY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 319 TURKEY PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 320 TURKEY ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 321 TURKEY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 322 TURKEY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 323 TURKEY BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 324 TURKEY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 325 TURKEY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 326 TURKEY ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 327 TURKEY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 328 TURKEY VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 329 TURKEY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 330 TURKEY INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 331 TURKEY ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 332 TURKEY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 333 TURKEY BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 334 TURKEY BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 335 TURKEY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 336 TURKEY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 337 TURKEY ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 338 TURKEY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 339 TURKEY VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 340 TURKEY BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 341 TURKEY ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 342 TURKEY ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 343 NETHERLANDS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 344 NETHERLANDS CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 345 NETHERLANDS ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 346 NETHERLANDS BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 347 NETHERLANDS BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 348 NETHERLANDS BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 349 NETHERLANDS BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 350 NETHERLANDS BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 351 NETHERLANDS ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 352 NETHERLANDS BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 353 NETHERLANDS VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 354 NETHERLANDS BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 355 NETHERLANDS PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 356 NETHERLANDS ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 357 NETHERLANDS BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 358 NETHERLANDS BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 359 NETHERLANDS BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 360 NETHERLANDS BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 361 NETHERLANDS BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 362 NETHERLANDS ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 363 NETHERLANDS BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 364 NETHERLANDS VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 365 NETHERLANDS BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 366 NETHERLANDS INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 367 NETHERLANDS ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 368 NETHERLANDS BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 369 NETHERLANDS BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 370 NETHERLANDS BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 371 NETHERLANDS BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 372 NETHERLANDS BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 373 NETHERLANDS ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 374 NETHERLANDS BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 375 NETHERLANDS VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 376 NETHERLANDS BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 377 NETHERLANDS ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 378 NETHERLANDS ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 379 SWITZERLAND ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 380 SWITZERLAND CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 381 SWITZERLAND ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 382 SWITZERLAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 383 SWITZERLAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 384 SWITZERLAND BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 385 SWITZERLAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 386 SWITZERLAND BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 387 SWITZERLAND ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 388 SWITZERLAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 389 SWITZERLAND VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 390 SWITZERLAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 391 SWITZERLAND PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 392 SWITZERLAND ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 393 SWITZERLAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 394 SWITZERLAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 395 SWITZERLAND BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 396 SWITZERLAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 397 SWITZERLAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 398 SWITZERLAND ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 399 SWITZERLAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 400 SWITZERLAND VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 401 SWITZERLAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 402 SWITZERLAND INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 403 SWITZERLAND ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 404 SWITZERLAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 405 SWITZERLAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 406 SWITZERLAND BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 407 SWITZERLAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 408 SWITZERLAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 409 SWITZERLAND ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 410 SWITZERLAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 411 SWITZERLAND VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 412 SWITZERLAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 413 SWITZERLAND ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 414 SWITZERLAND ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 415 BELGIUM ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 416 BELGIUM CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 417 BELGIUM ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 418 BELGIUM BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 419 BELGIUM BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 420 BELGIUM BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 421 BELGIUM BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 422 BELGIUM BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 423 BELGIUM ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 424 BELGIUM BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 425 BELGIUM VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 426 BELGIUM BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 427 BELGIUM PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 428 BELGIUM ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 429 BELGIUM BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 430 BELGIUM BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 431 BELGIUM BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 432 BELGIUM BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 433 BELGIUM BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 434 BELGIUM ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 435 BELGIUM BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 436 BELGIUM VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 437 BELGIUM BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 438 BELGIUM INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 439 BELGIUM ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 440 BELGIUM BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 441 BELGIUM BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 442 BELGIUM BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 443 BELGIUM BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 444 BELGIUM BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 445 BELGIUM ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 446 BELGIUM BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 447 BELGIUM VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 448 BELGIUM BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 449 BELGIUM ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION)
TABLE 450 BELGIUM ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 451 REST OF EUROPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
Liste des figures
FIGURE 1 EUROPE ANTHRAX TREATMENT MARKET: SEGMENTATION
FIGURE 2 EUROPE ANTHRAX TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE ANTHRAX TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 EUROPE ANTHRAX TREATMENT MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 EUROPE ANTHRAX TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE ANTHRAX TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE ANTHRAX TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE ANTHRAX TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 EUROPE ANTHRAX TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE ANTHRAX TREATMENT MARKET: SEGMENTATION
FIGURE 11 MIDDLE EAST & AFRICA IS ANTICIPATED TO DOMINATE THE ANTHRAX TREATMENT MARKET AND GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASING INCIDENCE AND PREVALENCE OF ANTHRAX INFECTIONS ARE EXPECTED TO DRIVE THE EUROPE ANTHRAX TREATMENT MARKET IN THE FORECAST PERIOD
FIGURE 13 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ANTHRAX TREATMENT MARKET IN 2022 & 2029
FIGURE 14 EUROPE DISTRIBUTION OF OUTBREAKS BY COUNTRY AND GEOGRAPHIC LOCATIONS OF ANTHRAX EVENTS-
FIGURE 15 PATHOPHYSIOLOGY OF ANTHRAX-
FIGURE 16 FLOW CHART FOR SUSPECTED ANTHRAX EXPOSURE-
FIGURE 17 GC BIOPHARMA ANTHRAX CANDIDATE GC1109 IS IN PHASE 2 (NCT01624532).
FIGURE 18 BA-ISTAB IS A FUSION OF A B. ANTHRACIS SPECIFIC CWT WITH A POTENT MONOCLONAL ANTIBODY THAT NEUTRALIZE ANTHRAX TOXIN (PA).
FIGURE 19 TWO ROUTES BY WHICH VACCINATION CAN REDUCE INCIDENCE OF AMR-
FIGURE 20 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE ANTHRAX TREATMENT MARKET
FIGURE 21 EUROPE ANTHRAX TREATMENT MARKET : TYPE, 2021
FIGURE 22 EUROPE ANTHRAX TREATMENT MARKET : TYPE, 2022-2029 (USD MILLION)
FIGURE 23 EUROPE ANTHRAX TREATMENT MARKET : TYPE, CAGR (2022-2029)
FIGURE 24 EUROPE ANTHRAX TREATMENT MARKET : TYPE, LIFELINE CURVE
FIGURE 25 EUROPE ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, 2021
FIGURE 26 EUROPE ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 27 EUROPE ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 28 EUROPE ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 29 EUROPE ANTHRAX TREATMENT MARKET : BY END USER, 2021
FIGURE 30 EUROPE ANTHRAX TREATMENT MARKET : BY END USER, 2022-2029 (USD MILLION)
FIGURE 31 EUROPE ANTHRAX TREATMENT MARKET : BY END USER, CAGR (2022-2029)
FIGURE 32 EUROPE ANTHRAX TREATMENT MARKET : BY END USER, LIFELINE CURVE
FIGURE 33 EUROPE ANTHRAX TREATMENT MARKET: SNAPSHOT (2021)
FIGURE 34 EUROPE ANTHRAX TREATMENT MARKET: BY COUNTRY (2021)
FIGURE 35 EUROPE ANTHRAX TREATMENT MARKET: BY COUNTRY (2022 & 2029)
FIGURE 36 EUROPE ANTHRAX TREATMENT MARKET: BY COUNTRY (2021 & 2029)
FIGURE 37 EUROPE ANTHRAX TREATMENT MARKET: BY TYPE (2022-2029)
FIGURE 38 EUROPE ANTHRAX TREATMENT MARKET: COMPANY SHARE 2021(%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
